User profiles for "author:Perry Demsko"
 | Perry DemskoPhD Candidate, University of Pennsylvania Verified email at pennmedicine.upenn.edu Cited by 8 |
[HTML][HTML] PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
E Baldelli, KA Hodge, G Bellezza, NJ Shah… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Anti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-
L1) agents are broadly used in first-line and second-line treatment across different tumor …
L1) agents are broadly used in first-line and second-line treatment across different tumor …
[HTML][HTML] Combination of a luspatercept-like drug (RAP-GRL) and Tmprss6-ASO is superior to either drug alone for correcting β-thalassemia
The hallmarks of β-thalassemia (BT) include ineffective erythropoiesis (IE), splenomegaly
and iron overload (IO). Recent studies have pointed to iron restriction (IR) to improve both …
and iron overload (IO). Recent studies have pointed to iron restriction (IR) to improve both …
Combination of a TGF-β Ligand Trap (RAP-GRL) and TMPRSS6-ASO Is Superior for Correcting β-Thalassemia
The hallmarks of β-thalassemia (BT) include ineffective erythropoiesis (IE) and iron overload
(IO). Our studies have pointed to iron restriction (IR) to improve both anemia and IO in BT …
(IO). Our studies have pointed to iron restriction (IR) to improve both anemia and IO in BT …
P1520: AN ACTIVIN RECEPTOR IIB LIGAND TRAP, IN COMBINATION WITH TMPRSS6 INDUCED IRON-RESTRICTION, IS A SUPERIOR TREATMENT FOR …
Background: The hallmarks of β-thalassemia (BT) include ineffective erythropoiesis (IE),
splenomegaly and iron overload (IO). There are several new promising therapetutics to treat …
splenomegaly and iron overload (IO). There are several new promising therapetutics to treat …
Antigen-Presenting Signaling Events in the Tumor Ecology Associate with Response to Anti-PD-1 Treatment in Lung Cancer
E Baldelli, KA Hodge, MJ Campbell, G Bellezza… - 2019 - papers.ssrn.com
Immune-checkpoint blockade has emerged as a powerful therapeutic strategy in lung
cancer. However, the molecular mechanisms associated with response are still poorly …
cancer. However, the molecular mechanisms associated with response are still poorly …